Get the SPI Wire

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP
Annual Meeting

of Shareholders

MEETING DATE

09/15/2026
DEF 14A FILED
08/03/2026
PUBLISHED
08/03/2026 8:05 pm
TIME TO PUBLISH
08/05/2026
METHODOLOGY
approve
EXCHANGE NASDAQ:ORMP · CUSIP 63008G203 · CLASS Common Stock · CIK 0001176309

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

6
FOR
0
AGAINST
0
WITHHOLD
6
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
Election of six directors to serve on our board of directors for a term of one year or until their successors are elected and qualified
board
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The filing names six nominees for one-year terms and each nominee has expressed an intention to serve.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
Ratification of the appointment of Kesselman & Kesselman as our independent registered public accounting firm for the fiscal year ending December 31, 2026
auditor
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The Audit Committee concluded Kesselman & Kesselman is independent and retention is in the Company’s best interests.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
Approval of the Third Amendment to the Oramed Pharmaceuticals Inc. Long-Term Incentive Plan to increase authorized shares by 3,000,000 to 12,500,000
compensation
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The filing states 958,245 shares remained available and the amendment would add 3,000,000 shares.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
Approval of, on a non-binding advisory basis, the compensation of our named executive officers
compensation
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The filing states the compensation program includes base salary and long-term equity incentives.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
5
Approval of, on a non-binding advisory basis, the frequency of future advisory votes on the compensation paid to our named executive officers
compensation
Elevated
For
Board none · Duopoly unknown — ⚠ Divergence flagged

The filing states equity awards vest over multi-year periods to encourage long-term performance.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.
6
Approval of a proposal to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies
other
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The filing states adjournment could permit further solicitation if votes are insufficient for one or more proposals.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

d0afc166531f21aeb8d3f74495eb13df2cecb3cf2991efbdca9518cb46329432

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates